Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia

Leuk Lymphoma. 2021 Mar;62(3):755-757. doi: 10.1080/10428194.2020.1842401. Epub 2020 Nov 5.

Authors

Monia Lunghi¹, Andrea Patriarca¹, Mariangela Greco¹, Akram Taherinasab², Irene Della Starza², Marzia Cavalli², Gianluca Gaidano¹, Robin Foà², Sabina Chiaretti²

Affiliations

¹ Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
² Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

PMID: 33150814
DOI: 10.1080/10428194.2020.1842401

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Imidazoles / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Pyridazines* / therapeutic use

Substances

Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib